Consensus on clinical management of tumor-induced osteomalacia  

作　　者：Yan Jiang Xiang Li Li Huo Yong Liu Wei Lyu Lian Zhou Wei Yu Huan-Wen Wu Xiao-Ping Xing Mei Li Ou Wang Yue Chi Rui-Zhi Jiajue Yu Pei Jian-Min Liu Jian-Ming Ba Qiao Zhang Zhi-Feng Sheng Zhen-Lin Zhang Jia-Jun Zhao Salvatore Minisola Wei-Bo Xia on behalf of Chinese Society of Osteoporosis and Bone Mineral Research and Chinese Society of Endocrinology 

机构地区：[1]Department of Endocrinology,Key Laboratory of Endocrinology,State Key Laboratory of Complex Severe and Rare Diseases,NHC,Peking Union Medical College Hospital,Chinese Academy of Medical Science and Peking Union Medical College,Beijing 100730,China [2]Department of Nuclear Medicine,Peking Union Medical College Hospital,Chinese Academy of Medical Science,Beijing 100730,China [3]Department of Orthopaedic Surgery,Peking Union Medical College Hospital,Chinese Academy of Medical Science,Beijing 100730,China [4]Department of ENT,Peking Union Medical College Hospital,Chinese Academy of Medical Science,Beijing 100730,China [5]Department of Stomatology,Peking Union Medical College Hospital,Chinese Academy of Medical Science,Beijing 100730,China [6]Department of Radiology,Peking Union Medical College Hospital,Chinese Academy of Medical Science,Beijing 100730,China [7]Department of Pathology,Peking Union Medical College Hospital,Chinese Academy of Medical Science,Beijing 100730,China [8]Department of Endocrinology,Chinese PLA General Hospital,Beijing 100853,China [9]Department of Endocrine and Metabolic Diseases,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai Institute of Endocrine and Metabolic Diseases,Shanghai Clinical Center for Endocrine and Metabolic Diseases,Shanghai 200025,China [10]Department of Endocrinology and Metabolism,Affiliated Hospital of Guiyang Medical University,Guiyang,Guizhou 550004,China [11]Department of Metabolism and Endocrinology,The Second Xiangya Hospital,Central South University,Changsha,Hunan 410011,China [12]Department of Osteoporosis and Bone Diseases,Shanghai Clinical Research Center of Bone Disease,Shanghai Jiao Tong University Affiliated Sixth People’s Hospital,Shanghai 200233,China [13]Department of Endocrinology and Metabolism,Shandong Provincial Hospital Affiliated to Shandong First Medical University,Jinan,Shandong 250021,China [14]Department of Internal Medicine and Medical Disciplines,Sapienza University of Rome,Rome,Italy [15]不详

出　　处：《Chinese Medical Journal》2021年第11期1264-1266,共3页中华医学杂志（英文版）

基　　金：by grants from the CAMS Innovation Fund for Medical Science(No.2016-I2M-3-003);the National Natural Science Foundation of China(No.81970757 and No.81670714).

摘　　要：Tumor-induced osteomalacia(TIO)is a rare paraneoplastic syndrome caused by excessive fibroblast growth factor 23(FGF23)production by a tumor,which often arises from a mesenchymal origin.[1-3]Most clinical symptoms of TIO are the consequences of prolonged FGF23-mediated hypophosphatemia as muscle weakness,bone pain,impaired mobility,and fractures.[4]Clinical diagnosis and management of TIO are challenging because knowledge about this condition is still restricted to a few specialized centers,leading to delay in diagnosis and appropriate treatment.The scope of the present consensus is to provide up-to-date guidance on the assessment and treatment of TIO.

关 键 词：DIAGNOSIS CLINICAL IMPAIRED 

分 类 号：R681[医药卫生—骨科学]